Holen Sie sich die Stockscreener-App
74.64
0.09%
0.292
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
Arrowhead and Madrigal sign global licence for MASH RNAi therapy - Yahoo Finance
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - Pharmaceutical Technology
ViaSat, Arrowhead Pharmaceuticals, and Sphere Entertainment Lead Stock Returns - Markets Mojo
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals - Arrowhead Pharmaceuticals, Inc.
Madrigal expands MASH pipeline in potential $1B Arrowhead deal - BioWorld News
Arrowhead Pharmaceuticals stock hits 52-week high at 77.23 USD - Investing.com
Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead - BioSpace
Biotechnology company Arrowhead Pharmaceuticals announces a major collaboration agreement with Madrigal Pharmaceuticals. - Bitget
Arrowhead licenses MASH drug candidate to Madrigal for $1B By Investing.com - Investing.com Canada
After 46% liver fat cut, Madrigal licenses Arrowhead MASH drug - Stock Titan
JPMorgan Expects Arrowhead Pharma Stock to Rally on RNAi Portfolio Growth - TIKR.com
MSN Money - MSN
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events - Business Wire
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Australian Approval Of REDEMPLO For FCS - Yahoo Finance
Arrowhead upgraded at Morgan Stanley on upcoming catalysts - MSN
Is Arrowhead Pharmaceuticals (ARWR) Stock Price Out Of Line With Recent 1-Year Surge? - Sahm
Kornitzer Capital Management Inc. KS Makes New $2.38 Million Investment in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential - Insider Monkey
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Vanguard Group Inc. - MarketBeat
ARWR Initiates Coverage By JP Morgan -- Rating Set to Overweight - GuruFocus
ARWR SEC FilingsArrowhead Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Now Covered by JPMorgan Chase & Co. - MarketBeat
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS) - Arrowhead Pharmaceuticals, Inc.
J.P. Morgan Initiates Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Announces Target Price $88 - Moomoo
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
JPMorgan initiates Arrowhead Pharma stock coverage with overweight rating - Investing.com
JP Morgan Initiates Coverage of Arrowhead Pharmaceuticals (ARWR) with Overweight Recommendation - MSN
Arrowhead Pharmaceuticals | SCHEDULE 13G: Others - Moomoo
5 Most Profitable Biotech Stocks to Buy Now - Insider Monkey
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.
Behavioral Patterns of ARWR and Institutional Flows - Stock Traders Daily
Arrowhead Pharmaceuticals (ARWR) Projected to Post Earnings on Thursday - MarketBeat
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Vanguard reports 5.05% stake in Arrowhead Pharmaceuticals (ARWR) - Stock Titan
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Acquired by Pictet Asset Management Holding SA - MarketBeat
Vanguard Portfolio Management (NASDAQ: ARWR) reports 5.19% stake in Arrowhead - Stock Titan
FengHe Fund Management Pte. Ltd. Makes New $17.71 Million Investment in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead rises as FDA approves lead drug for rare disorder - msn.com
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome in Europe - marketscreener.com
Sarepta sells Arrowhead stock, activates $100M milestone payment - MSN
Arrowhead Pharmaceuticals (ARWR) price target increased by 23.01% to 77.60 - MSN
Insider Sell: James Hamilton Sells 10,000 Shares of Arrowhead Ph - GuruFocus
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider Sells 10,000 Shares of Stock - MarketBeat
Arrowhead (NASDAQ: ARWR) CMO sells 10,000 pre-planned shares - Stock Titan
Arrowhead CFO Daniel Apel sells $934,285 in company stock By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals CMO James Hamilton sells $750,000 in stock By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals CMO James Hamilton sells $750,000 in stock - Investing.com UK
Arrowhead CFO Daniel Apel sells $934,285 in company stock - Investing.com
Arrowhead (ARWR) CFO Apel sells 13,095 shares in Rule 10b5-1 trades - Stock Titan
BlackRock holds 12.2% of Arrowhead Pharmaceuticals (NASDAQ: ARWR) in 13G/A - Stock Titan
Sanofi, Arrowhead, Novartis win CHMP backing (SNY:NASDAQ) - Seeking Alpha
Arrowhead (ARWR) Secures Positive EMA Opinion for REDEMPLO in FC - GuruFocus
0.78%
3.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):